BC_Immune.Evasion

MHC II antigen presentation is the major pathway associated with progression-free survival between transcriptionally categorized TNBCs.The effect of MHC II on the prognosis of clinically stratified breast cancers (BC) based on receptors (i.e., estrogen, progesterone and HER2) has not been addressed. To study the MHC II in different BC subtypes, we conducted differential gene expression analysis following by network analysis across clinically stratified BCs. To do so, we analyzed transcriptomics (scRNA-seq) and proteomics (quantitative proteomics from cell lines) profiles of malignant epithelial cells. We confirmed our findings in chromatin level using ATAC-seq data analysis.